Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells $1,001,110.00 in Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) major shareholder Global Strategic Fund I. Venbio sold 95,800 shares of the stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $10.45, for a total transaction of $1,001,110.00. Following the transaction, the insider now owns 2,155,930 shares in the company, valued at $22,529,468.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ CMPI opened at $10.47 on Wednesday. Checkmate Pharmaceuticals, Inc. has a 52 week low of $2.00 and a 52 week high of $10.48. The firm’s fifty day moving average is $6.12 and its 200 day moving average is $4.19. The company has a market cap of $230.76 million, a price-to-earnings ratio of -3.59 and a beta of -4.86.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter. As a group, equities analysts predict that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Decheng Capital Management III Cayman LLC bought a new position in Checkmate Pharmaceuticals during the 1st quarter valued at approximately $4,253,000. Millennium Management LLC purchased a new position in shares of Checkmate Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, BlackRock Inc. raised its holdings in shares of Checkmate Pharmaceuticals by 126.7% during the third quarter. BlackRock Inc. now owns 51,794 shares of the company’s stock valued at $205,000 after acquiring an additional 28,944 shares in the last quarter. 74.56% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently issued reports on the stock. BTIG Research cut shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 20th. Zacks Investment Research raised Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 3rd.

About Checkmate Pharmaceuticals (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Featured Stories

Insider Buying and Selling by Quarter for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.